

Derivation of lead candidates for idiopathic pulmonary fibrosis treatment through inhalant optimization of integrin selective binding peptide.



RESPIRATORY	Lead
Product Type	Peptide
Indication	Idiopathic pulmonary fibrosis
Target	Integrins
MoA(Mechanism of Action)	Binds to integrins and interrupts the interaction of TGF beta signaling.
Competitiveness	Development as a peptides drug with high delivery efficiency, efficacy, and low side effects compared to competitors.
Development Stage	Lead
Route of Administration	Inhalation